LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Athanassios Argiris, Kevin J. Harrington, Makoto Tahara, Robert L. Ferris, Maura L. Gillison, Jérôme Fayette, Amaury Daste, P. Koralewski, R. Mesía Nin, Nabil F. Saba, Milena Perez Mak, Miguel Ángel Álvarez-Avitia, Alexander Guminski, Urs Müller‐Richter, Naomi Kiyota, Mustimbo Roberts, Talal Khan, Karen Miller-Moslin, Wei Li, R. Haddad